nach oben

Endocrine

Erschienen in:

16.01.2024 | Review

Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis

verfasst von: Yi Pan, Tong Bu, Xia Deng, Jue Jia, Guoyue Yuan

Erschienen in: Endocrine | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Type 2 diabetes mellitus (T2DM) has become one of the most serious public healthcare challenges, contributing to increased mortality and disability. In the past decades, significant progress has been made in understanding the pathogenesis of T2DM. Mounting evidence suggested that gut microbiota (GM) plays a significant role in the development of T2DM. Communication between the GM and the brain is a complex bidirectional connection, known as the “gut-brain axis,” via the nervous, neuroendocrine, and immune systems. Gut-brain axis has an essential impact on various physiological processes, including glucose metabolism, food intake, gut motility, etc. In this review, we provide an outline of the gut-brain axis. We also highlight how the dysbiosis of the gut-brain axis affects glucose homeostasis and even results in T2DM.

H. Sun, P. Saeedi, S. Karuranga, M. Pinkepank, K. Ogurtsova, B.B. Duncan, C. Stein, A. Basit, J.C.N. Chan, J.C. Mbanya, M.E. Pavkov, A. Ramachandaran, S.H. Wild, S. James, W.H. Herman, P. Zhang, C. Bommer, S. Kuo, E.J. Boyko, D.J. Magliano, IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pr. 183, 109119 (2022). https://doi.org/10.1016/j.diabres.2021.109119CrossRef

M.N. Huda, M. Kim, B.J. Bennett, Modulating the microbiota as a therapeutic intervention for type 2 diabetes. Front. Endocrinol. 12, 632335 (2021). https://doi.org/10.3389/fendo.2021.632335CrossRef

S. Chatterjee, K. Khunti, M.J. Davies, Type 2 diabetes. Lancet 389(10085), 2239–2251 (2017). https://doi.org/10.1016/s0140-6736(17)30058-2CrossRefPubMed

M. Gurung, Z. Li, H. You, R. Rodrigues, D.B. Jump, A. Morgun, N. Shulzhenko, Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine 51, 102590 (2020). https://doi.org/10.1016/j.ebiom.2019.11.051CrossRefPubMedPubMedCentral

M. Zhao, J. Chu, S. Feng, C. Guo, B. Xue, K. He, L. Li, Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review. Biomed. Pharmacother. 164, 114985 (2023). https://doi.org/10.1016/j.biopha.2023.114985CrossRefPubMed

A. Jais, J.C. Brüning, Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus. Endocr. Rev. 43(2), 314–328 (2022). https://doi.org/10.1210/endrev/bnab025CrossRefPubMed

W.R. Wikoff, A.T. Anfora, J. Liu, P.G. Schultz, S.A. Lesley, E.C. Peters, G. Siuzdak, Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106(10), 3698–3703 (2009). https://doi.org/10.1073/pnas.0812874106CrossRefPubMedPubMedCentral

J.M. Yano, K. Yu, G.P. Donaldson, G.G. Shastri, P. Ann, L. Ma, C.R. Nagler, R.F. Ismagilov, S.K. Mazmanian, E.Y. Hsiao, Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 161(2), 264–276 (2015). https://doi.org/10.1016/j.cell.2015.02.047CrossRefPubMedPubMedCentral

B.S. Samuel, A. Shaito, T. Motoike, F.E. Rey, F. Backhed, J.K. Manchester, R.E. Hammer, S.C. Williams, J. Crowley, M. Yanagisawa, J.I. Gordon, Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105(43), 16767–16772 (2008). https://doi.org/10.1073/pnas.0808567105CrossRefPubMedPubMedCentral

10.

P.V. Bauer, S.C. Hamr, F.A. Duca, Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. Cell Mol. Life Sci. 73(4), 737–755 (2016). https://doi.org/10.1007/s00018-015-2083-zCrossRefPubMed

11.

C. Lee, H. Lee, J.C. Park, S.H. Im, Microbial components and effector molecules in T Helper cell differentiation and function. Immune Netw. 23(1), e7 (2023). https://doi.org/10.4110/in.2023.23.e7CrossRefPubMedPubMedCentral

12.

J. Qin, R. Li, J. Raes, M. Arumugam, K.S. Burgdorf, C. Manichanh, T. Nielsen, N. Pons, F. Levenez, T. Yamada, D.R. Mende, J. Li, J. Xu, S. Li, D. Li, J. Cao, B. Wang, H. Liang, H. Zheng, Y. Xie, J. Tap, P. Lepage, M. Bertalan, J.M. Batto, T. Hansen, D. Le Paslier, A. Linneberg, H.B. Nielsen, E. Pelletier, P. Renault, T. Sicheritz-Ponten, K. Turner, H. Zhu, C. Yu, S. Li, M. Jian, Y. Zhou, Y. Li, X. Zhang, S. Li, N. Qin, H. Yang, J. Wang, S. Brunak, J. Doré, F. Guarner, K. Kristiansen, O. Pedersen, J. Parkhill, J. Weissenbach, P. Bork, S.D. Ehrlich, J. Wang, A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285), 59–65 (2010). https://doi.org/10.1038/nature08821CrossRefPubMedPubMedCentral

13.

C. de Weerth, Do bacteria shape our development? Crosstalk between intestinal microbiota and HPA axis. Neurosci. Biobehav. Rev. 83, 458–471 (2017). https://doi.org/10.1016/j.neubiorev.2017.09.016CrossRefPubMed

14.

A. El-Sayed, L. Aleya, M. Kamel, Microbiota’s role in health and diseases. Environ. Sci. Pollut. Res. Int. 28(28), 36967–36983 (2021). https://doi.org/10.1007/s11356-021-14593-zCrossRefPubMedPubMedCentral

15.

H. Ullah, S. Arbab, Y. Tian, C.Q. Liu, Y. Chen, L. Qijie, M.I.U. Khan, I.U. Hassan, K. Li, The gut microbiota-brain axis in neurological disorder. Front. Neurosci. 17, 1225875 (2023). https://doi.org/10.3389/fnins.2023.1225875CrossRefPubMedPubMedCentral

16.

P.B. Eckburg, E.M. Bik, C.N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S.R. Gill, K.E. Nelson, D.A. Relman, Diversity of the human intestinal microbial flora. Science 308(5728), 1635–1638 (2005). https://doi.org/10.1126/science.1110591CrossRefPubMedPubMedCentral

17.

C. Barrio, S. Arias-Sánchez, I. Martín-Monzón, The gut microbiota-brain axis, psychobiotics and its influence on brain and behaviour: a systematic review. Psychoneuroendocrinology 137, 105640 (2022). https://doi.org/10.1016/j.psyneuen.2021.105640CrossRefPubMed

18.

C.S. Oriach, R.C. Robertson, C. Stanton, J.F. Cryan, T.G. Dinan, Food for thought: the role of nutrition in the microbiota–gut–brain axis. Clin. Nutr. Exp. 6, 25–38 (2016). https://doi.org/10.1016/j.yclnex.2016.01.003CrossRef

19.

Y. Chen, J. Zhou, L. Wang, Role and mechanism of gut microbiota in human disease. Front. Cell Infect. Microbiol. 11, 625913 (2021). https://doi.org/10.3389/fcimb.2021.625913CrossRefPubMedPubMedCentral

20.

A. Varesi, L.I.M. Campagnoli, F. Fahmideh, E. Pierella, M. Romeo, G. Ricevuti, M. Nicoletta, S. Chirumbolo, and A. Pascale, The interplay between gut microbiota and Parkinson’s disease: implications on diagnosis and treatment. Int. J. Mol. Sci. 23(20), (2022). https://doi.org/10.3390/ijms232012289

21.

A. Varesi, L.I.M. Campagnoli, S. Chirumbolo, B. Candiano, A. Carrara, G. Ricevuti, C. Esposito, A. Pascale, The brain-gut-microbiota interplay in depression: a key to design innovative therapeutic approaches. Pharm. Res. 192, 106799 (2023). https://doi.org/10.1016/j.phrs.2023.106799CrossRef

22.

L.I.M. Campagnoli, N. Marchesi, M. Vairetti, A. Pascale, A. Ferrigno, and A. Barbieri, Age-related NAFLD: the use of probiotics as a supportive therapeutic intervention. Cells 11(18), (2022). https://doi.org/10.3390/cells11182827

23.

F. Suriano, S. Vieira-Silva, G. Falony, M. Roumain, A. Paquot, R. Pelicaen, M. Régnier, N.M. Delzenne, J. Raes, G.G. Muccioli, M. Van Hul, P.D. Cani, Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome 9(1), 147 (2021). https://doi.org/10.1186/s40168-021-01097-8CrossRefPubMedPubMedCentral

24.

F. Yu, W. Han, G. Zhan, S. Li, X. Jiang, L. Wang, S. Xiang, B. Zhu, L. Yang, A. Luo, F. Hua, C. Yang, Abnormal gut microbiota composition contributes to the development of type 2 diabetes mellitus in db/db mice. Aging 11(22), 10454–10467 (2019). https://doi.org/10.18632/aging.102469CrossRefPubMedPubMedCentral

25.

P.P. Zhang, L.L. Li, X. Han, Q.W. Li, X.H. Zhang, J.J. Liu, Y. Wang, Fecal microbiota transplantation improves metabolism and gut microbiome composition in db/db mice. Acta Pharm. Sin. 41(5), 678–685 (2020). https://doi.org/10.1038/s41401-019-0330-9CrossRef

26.

N. Larsen, F.K. Vogensen, F.W. van den Berg, D.S. Nielsen, A.S. Andreasen, B.K. Pedersen, W.A. Al-Soud, S.J. Sørensen, L.H. Hansen, M. Jakobsen, Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2), e9085 (2010). https://doi.org/10.1371/journal.pone.0009085CrossRefPubMedPubMedCentral

27.

J. Qin, Y. Li, Z. Cai, S. Li, J. Zhu, F. Zhang, S. Liang, W. Zhang, Y. Guan, D. Shen, Y. Peng, D. Zhang, Z. Jie, W. Wu, Y. Qin, W. Xue, J. Li, L. Han, D. Lu, P. Wu, Y. Dai, X. Sun, Z. Li, A. Tang, S. Zhong, X. Li, W. Chen, R. Xu, M. Wang, Q. Feng, M. Gong, J. Yu, Y. Zhang, M. Zhang, T. Hansen, G. Sanchez, J. Raes, G. Falony, S. Okuda, M. Almeida, E. LeChatelier, P. Renault, N. Pons, J.M. Batto, Z. Zhang, H. Chen, R. Yang, W. Zheng, S. Li, H. Yang, J. Wang, S.D. Ehrlich, R. Nielsen, O. Pedersen, K. Kristiansen, J. Wang, A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490(7418), 55–60 (2012). https://doi.org/10.1038/nature11450CrossRefPubMed

28.

Q. Li, Y. Chang, K. Zhang, H. Chen, S. Tao, Z. Zhang, Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci. Rep. 10(1), 5450 (2020). https://doi.org/10.1038/s41598-020-62224-3CrossRefPubMedPubMedCentral

29.

F.H. Karlsson, V. Tremaroli, I. Nookaew, G. Bergström, C.J. Behre, B. Fagerberg, J. Nielsen, F. Bäckhed, Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452), 99–103 (2013). https://doi.org/10.1038/nature12198CrossRefPubMed

30.

P.C. Chen, Y.W. Chien, S.C. Yang, The alteration of gut microbiota in newly diagnosed type 2 diabetic patients. Nutrition 63-64, 51–56 (2019). https://doi.org/10.1016/j.nut.2018.11.019CrossRefPubMed

31.

K.H. Allin, V. Tremaroli, R. Caesar, B.A.H. Jensen, M.T.F. Damgaard, M.I. Bahl, T.R. Licht, T.H. Hansen, T. Nielsen, T.M. Dantoft, A. Linneberg, T. Jørgensen, H. Vestergaard, K. Kristiansen, P.W. Franks, T. Hansen, F. Bäckhed, O. Pedersen, Aberrant intestinal microbiota in individuals with prediabetes. Diabetologia 61(4), 810–820 (2018). https://doi.org/10.1007/s00125-018-4550-1CrossRefPubMedPubMedCentral

32.

T. Xu, Y. Ge, H. Du, Q. Li, X. Xu, H. Yi, X. Wu, T. Kuang, G. Fan, Y. Zhang, Berberis kansuensis extract alleviates type 2 diabetes in rats by regulating gut microbiota composition. J. Ethnopharmacol. 273, 113995 (2021). https://doi.org/10.1016/j.jep.2021.113995CrossRefPubMed

33.

J. Xu, R. Liang, W. Zhang, K. Tian, J. Li, X. Chen, T. Yu, Q. Chen, Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J. Diabetes 12(3), 224–236 (2020). https://doi.org/10.1111/1753-0407.12986CrossRefPubMed

34.

S. Singh, R.K. Sharma, S. Malhotra, R. Pothuraju, U.K. Shandilya, Lactobacillus rhamnosus NCDC17 ameliorates type-2 diabetes by improving gut function, oxidative stress and inflammation in high-fat-diet fed and streptozotocintreated rats. Benef. Microbes 8(2), 243–255 (2017). https://doi.org/10.3920/bm2016.0090CrossRefPubMed

35.

S. Westfall, N. Lomis, I. Kahouli, S.Y. Dia, S.P. Singh, S. Prakash, Microbiome, probiotics, and neurodegenerative diseases: deciphering the gut-brain axis. Cell Mol. Life Sci. 74(20), 3769–3787 (2017). https://doi.org/10.1007/s00018-017-2550-9CrossRefPubMed

36.

C. Long-Smith, K.J. O’Riordan, G. Clarke, C. Stanton, T.G. Dinan, J.F. Cryan, Microbiota-gut-brain axis: new therapeutic opportunities. Annu. Rev. Pharm. Toxicol. 60, 477–502 (2020). https://doi.org/10.1146/annurev-pharmtox-010919-023628CrossRef

37.

H.R. Wachsmuth, S.N. Weninger, F.A. Duca, Role of the gut-brain axis in energy and glucose metabolism. Exp. Mol. Med. 54(4), 377–392 (2022). https://doi.org/10.1038/s12276-021-00677-wCrossRefPubMedPubMedCentral

38.

M. Rao, M.D. Gershon, The bowel and beyond: the enteric nervous system in neurological disorders. Nat. Rev. Gastroenterol. Hepatol. 13(9), 517–528 (2016). https://doi.org/10.1038/nrgastro.2016.107CrossRefPubMedPubMedCentral

39.

A.M. Goldstein, R.M. Hofstra, A.J. Burns, Building a brain in the gut: development of the enteric nervous system. Clin. Genet 83(4), 307–316 (2013). https://doi.org/10.1111/cge.12054CrossRefPubMed

40.

B. Niesler, S. Kuerten, I.E. Demir, K.H. Schäfer, Disorders of the enteric nervous system - a holistic view. Nat. Rev. Gastroenterol. Hepatol. 18(6), 393–410 (2021). https://doi.org/10.1038/s41575-020-00385-2CrossRefPubMed

41.

L.M.T. Dicks, Gut Bacteria and Neurotransmitters. Microorganisms 10(9), (2022). https://doi.org/10.3390/microorganisms10091838

42.

M. Schemann, Control of gastrointestinal motility by the “gut brain”–the enteric nervous system. J. Pediatr. Gastroenterol. Nutr. 41 Suppl 1, S4–S6 (2005). https://doi.org/10.1097/01.scs.0000180285.51365.55CrossRefPubMed

43.

J.F. Cryan, K.J. O’Riordan, C.S.M. Cowan, K.V. Sandhu, T.F.S. Bastiaanssen, M. Boehme, M.G. Codagnone, S. Cussotto, C. Fulling, A.V. Golubeva, K.E. Guzzetta, M. Jaggar, C.M. Long-Smith, J.M. Lyte, J.A. Martin, A. Molinero-Perez, G. Moloney, E. Morelli, E. Morillas, R. O’Connor, J.S. Cruz-Pereira, V.L. Peterson, K. Rea, N.L. Ritz, E. Sherwin, S. Spichak, E.M. Teichman, M. van de Wouw, A.P. Ventura-Silva, S.E. Wallace-Fitzsimons, N. Hyland, G. Clarke, T.G. Dinan, The microbiota-gut-brain axis. Physiol. Rev. 99(4), 1877–2013 (2019). https://doi.org/10.1152/physrev.00018.2018CrossRefPubMed

44.

S. Breit, A. Kupferberg, G. Rogler, G. Hasler, Vagus nerve as modulator of the brain-gut axis in psychiatric and inflammatory disorders. Front. Psychiatry 9, 44 (2018). https://doi.org/10.3389/fpsyt.2018.00044CrossRefPubMedPubMedCentral

45.

H. Ahmed, Q. Leyrolle, V. Koistinen, O. Kärkkäinen, S. Layé, N. Delzenne, K. Hanhineva, Microbiota-derived metabolites as drivers of gut-brain communication. Gut Microbes 14(1), 2102878 (2022). https://doi.org/10.1080/19490976.2022.2102878CrossRefPubMedPubMedCentral

46.

S. Fried, E. Wemelle, P.D. Cani, C. Knauf, Interactions between the microbiota and enteric nervous system during gut-brain disorders. Neuropharmacology 197, 108721 (2021). https://doi.org/10.1016/j.neuropharm.2021.108721CrossRefPubMed

47.

A. Bessac, P.D. Cani, E. Meunier, G. Dietrich, C. Knauf, Inflammation and gut-brain axis during type 2 diabetes: focus on the crosstalk between intestinal immune cells and enteric nervous system. Front. Neurosci. 12, 725 (2018). https://doi.org/10.3389/fnins.2018.00725CrossRefPubMedPubMedCentral

48.

A. Abot, A. Lucas, T. Bautzova, A. Bessac, A. Fournel, S. Le-Gonidec, P. Valet, C. Moro, P.D. Cani, C. Knauf, Galanin enhances systemic glucose metabolism through enteric nitric oxide synthase-expressed neurons. Mol. Metab. 10, 100–108 (2018). https://doi.org/10.1016/j.molmet.2018.01.020CrossRefPubMedPubMedCentral

49.

B. Chandrasekharan, S. Srinivasan, Diabetes and the enteric nervous system. Neurogastroenterol. Motil. 19(12), 951–960 (2007). https://doi.org/10.1111/j.1365-2982.2007.01023.xCrossRefPubMedPubMedCentral

50.

H. Iwasaki, M. Kajimura, S. Osawa, S. Kanaoka, T. Furuta, M. Ikuma, A. Hishida, A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with type 2 diabetes mellitus. J. Gastroenterol. 41(11), 1076–1087 (2006). https://doi.org/10.1007/s00535-006-1909-8CrossRefPubMed

51.

S.S. Yarandi, S. Srinivasan, Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol. Motil. 26(5), 611–624 (2014). https://doi.org/10.1111/nmo.12330CrossRefPubMedPubMedCentral

52.

A. Fournel, A. Drougard, T. Duparc, A. Marlin, S.M. Brierley, J. Castro, S. Le-Gonidec, B. Masri, A. Colom, A. Lucas, P. Rousset, N. Cenac, N. Vergnolle, P. Valet, P.D. Cani, C. Knauf, Apelin targets gut contraction to control glucose metabolism via the brain. Gut 66(2), 258–269 (2017). https://doi.org/10.1136/gutjnl-2015-310230CrossRefPubMed

53.

F. De Vadder, E. Grasset, L. Mannerås Holm, G. Karsenty, A.J. Macpherson, L.E. Olofsson, F. Bäckhed, Gut microbiota regulates maturation of the adult enteric nervous system via enteric serotonin networks. Proc. Natl Acad. Sci. USA 115(25), 6458–6463 (2018). https://doi.org/10.1073/pnas.1720017115CrossRefPubMedPubMedCentral

54.

T.M.Z. Waise, H.J. Dranse, T.K.T. Lam, The metabolic role of vagal afferent innervation. Nat. Rev. Gastroenterol. Hepatol. 15(10), 625–636 (2018). https://doi.org/10.1038/s41575-018-0062-1CrossRefPubMed

55.

B. Bonaz, T. Bazin, S. Pellissier, The vagus nerve at the interface of the microbiota-gut-brain axis. Front. Neurosci. 12, 49 (2018). https://doi.org/10.3389/fnins.2018.00049CrossRefPubMedPubMedCentral

56.

E.K. Williams, R.B. Chang, D.E. Strochlic, B.D. Umans, B.B. Lowell, S.D. Liberles, Sensory neurons that detect stretch and nutrients in the digestive system. Cell 166(1), 209–221 (2016). https://doi.org/10.1016/j.cell.2016.05.011CrossRefPubMedPubMedCentral

57.

L.H. Morais, H.L.T. Schreiber, S.K. Mazmanian, The gut microbiota-brain axis in behaviour and brain disorders. Nat. Rev. Microbiol. 19(4), 241–255 (2021). https://doi.org/10.1038/s41579-020-00460-0CrossRefPubMed

58.

M.S. Vohra, K. Benchoula, C.J. Serpell, W.E. Hwa, AgRP/NPY and POMC neurons in the arcuate nucleus and their potential role in treatment of obesity. Eur. J. Pharm. 915, 174611 (2022). https://doi.org/10.1016/j.ejphar.2021.174611CrossRef

59.

Z. Mirzadeh, C.L. Faber, M.W. Schwartz, Central nervous system control of glucose homeostasis: a therapeutic target for type 2 diabetes. Annu. Rev. Pharm. Toxicol. 62, 55–84 (2022). https://doi.org/10.1146/annurev-pharmtox-052220-010446CrossRef

60.

A. Plamboeck, S. Veedfald, C.F. Deacon, B. Hartmann, A. Wettergren, L.B. Svendsen, S. Meisner, C. Hovendal, F.K. Knop, T. Vilsbøll, J.J. Holst, Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. Eur. J. Endocrinol. 169(2), 187–201 (2013). https://doi.org/10.1530/eje-13-0264CrossRefPubMedPubMedCentral

61.

S.C. Payne, G. Ward, J.B. Fallon, T. Hyakumura, J.B. Prins, S. Andrikopoulos, R.J. MacIsaac, J. Villalobos, Blood glucose modulation and safety of efferent vagus nerve stimulation in a type 2 diabetic rat model. Physiol. Rep. 10(8), e15257 (2022). https://doi.org/10.14814/phy2.15257CrossRefPubMedPubMedCentral

62.

D. Borgmann, E. Ciglieri, N. Biglari, C. Brandt, A.L. Cremer, H. Backes, M. Tittgemeyer, F.T. Wunderlich, J.C. Brüning, H. Fenselau, Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism. Cell Metab. 33(7), 1466–1482.e7 (2021). https://doi.org/10.1016/j.cmet.2021.05.002CrossRefPubMedPubMedCentral

63.

P.Y. Wang, L. Caspi, C.K. Lam, M. Chari, X. Li, P.E. Light, R. Gutierrez-Juarez, M. Ang, G.J. Schwartz, T.K. Lam, Upper intestinal lipids trigger a gut-brain-liver axis to regulate glucose production. Nature 452(7190), 1012–1016 (2008). https://doi.org/10.1038/nature06852CrossRefPubMed

64.

L. Du, Q. Li, H. Yi, T. Kuang, Y. Tang, G. Fan, Gut microbiota-derived metabolites as key actors in type 2 diabetes mellitus. Biomed. Pharmacother. 149, 112839 (2022). https://doi.org/10.1016/j.biopha.2022.112839CrossRefPubMed

65.

D. Parada Venegas, M.K. De la Fuente, G. Landskron, M.J. González, R. Quera, G. Dijkstra, H.J.M. Harmsen, K.N. Faber, M.A. Hermoso, Short Chain Fatty Acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Front. Immunol. 10, 277 (2019). https://doi.org/10.3389/fimmu.2019.00277CrossRefPubMedPubMedCentral

66.

L. Liu, J.R. Huh, K. Shah, Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. EBioMedicine 77, 103908 (2022). https://doi.org/10.1016/j.ebiom.2022.103908CrossRefPubMedPubMedCentral

67.

B. van der Hee, J.M. Wells, Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 29(8), 700–712 (2021). https://doi.org/10.1016/j.tim.2021.02.001CrossRefPubMed

68.

X. Li, Y. Shimizu, I. Kimura, Gut microbial metabolite short-chain fatty acids and obesity. Biosci. Microbiota Food Health 36(4), 135–140 (2017). https://doi.org/10.12938/bmfh.17-010CrossRefPubMedPubMedCentral

69.

R. Corrêa-Oliveira, J.L. Fachi, A. Vieira, F.T. Sato, M.A. Vinolo, Regulation of immune cell function by short-chain fatty acids. Clin. Transl. Immunol. 5(4), e73 (2016). https://doi.org/10.1038/cti.2016.17CrossRef

70.

J.C. McNelis, Y.S. Lee, R. Mayoral, R. van der Kant, A.M. Johnson, J. Wollam, J.M. Olefsky, GPR43 potentiates β-cell function in obesity. Diabetes 64(9), 3203–3217 (2015). https://doi.org/10.2337/db14-1938CrossRefPubMedPubMedCentral

71.

A. Veprik, D. Laufer, S. Weiss, N. Rubins, M.D. Walker, GPR41 modulates insulin secretion and gene expression in pancreatic β-cells and modifies metabolic homeostasis in fed and fasting states. Faseb J. 30(11), 3860–3869 (2016). https://doi.org/10.1096/fj.201500030RCrossRefPubMed

72.

M. Thangaraju, G.A. Cresci, K. Liu, S. Ananth, J.P. Gnanaprakasam, D.D. Browning, J.D. Mellinger, S.B. Smith, G.J. Digby, N.A. Lambert, P.D. Prasad, V. Ganapathy, GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69(7), 2826–2832 (2009). https://doi.org/10.1158/0008-5472.Can-08-4466CrossRefPubMedPubMedCentral

73.

R.G. Xiong, D.D. Zhou, S.X. Wu, S.Y. Huang, A. Saimaiti, Z.J. Yang, A. Shang, C.N. Zhao, R.Y. Gan, and H.B. Li, Health benefits and side effects of short-chain fatty acids. Foods 11(18), (2022). https://doi.org/10.3390/foods11182863

74.

E.E. Canfora, J.W. Jocken, E.E. Blaak, Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11(10), 577–591 (2015). https://doi.org/10.1038/nrendo.2015.128CrossRefPubMed

75.

L. Jiang, B.I. Gulanski, H.M. De Feyter, S.A. Weinzimer, B. Pittman, E. Guidone, J. Koretski, S. Harman, I.L. Petrakis, J.H. Krystal, G.F. Mason, Increased brain uptake and oxidation of acetate in heavy drinkers. J. Clin. Invest. 123(4), 1605–1614 (2013). https://doi.org/10.1172/jci65153CrossRefPubMedPubMedCentral

76.

G. Frost, M.L. Sleeth, M. Sahuri-Arisoylu, B. Lizarbe, S. Cerdan, L. Brody, J. Anastasovska, S. Ghourab, M. Hankir, S. Zhang, D. Carling, J.R. Swann, G. Gibson, A. Viardot, D. Morrison, E. Louise Thomas, J.D. Bell, The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat. Commun. 5, 3611 (2014). https://doi.org/10.1038/ncomms4611CrossRefPubMed

77.

A. Psichas, M.L. Sleeth, K.G. Murphy, L. Brooks, G.A. Bewick, A.C. Hanyaloglu, M.A. Ghatei, S.R. Bloom, G. Frost, The short-chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents. Int J. Obes. 39(3), 424–429 (2015). https://doi.org/10.1038/ijo.2014.153CrossRef

78.

P. Louis, H.J. Flint, Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol. Lett. 294(1), 1–8 (2009). https://doi.org/10.1111/j.1574-6968.2009.01514.xCrossRefPubMed

79.

C. Alexander, K.S. Swanson, G.C. Fahey, K.A. Garleb, Perspective: physiologic importance of short-chain fatty acids from nondigestible carbohydrate fermentation. Adv. Nutr. 10(4), 576–589 (2019). https://doi.org/10.1093/advances/nmz004CrossRefPubMedPubMedCentral

80.

S.S. Pedersen, M. Prause, C. Sørensen, J. Størling, T. Moritz, E. Mariño, and N. Billestrup, Targeted delivery of butyrate improves glucose homeostasis, reduces hepatic lipid accumulation and inflammation in db/db mice. Int. J. Mol. Sci. 24(5), (2023). https://doi.org/10.3390/ijms24054533

81.

H. Wu, V. Tremaroli, C. Schmidt, A. Lundqvist, L.M. Olsson, M. Krämer, A. Gummesson, R. Perkins, G. Bergström, F. Bäckhed, The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study. Cell Metab. 32(3), 379–390.e3 (2020). https://doi.org/10.1016/j.cmet.2020.06.011CrossRefPubMed

82.

K. Ray, Gut microbiota: microbial metabolites feed into the gut-brain-gut circuit during host metabolism. Nat. Rev. Gastroenterol. Hepatol. 11(2), 76 (2014). https://doi.org/10.1038/nrgastro.2014.8CrossRefPubMed

83.

R. Li, S. Andreu-Sánchez, F. Kuipers, J. Fu, Gut microbiome and bile acids in obesity-related diseases. Best. Pr. Res Clin. Endocrinol. Metab. 35(3), 101493 (2021). https://doi.org/10.1016/j.beem.2021.101493CrossRef

84.

M.S. Trabelsi, M. Daoudi, J. Prawitt, S. Ducastel, V. Touche, S.I. Sayin, A. Perino, C.A. Brighton, Y. Sebti, J. Kluza, O. Briand, H. Dehondt, E. Vallez, E. Dorchies, G. Baud, V. Spinelli, N. Hennuyer, S. Caron, K. Bantubungi, R. Caiazzo, F. Reimann, P. Marchetti, P. Lefebvre, F. Bäckhed, F.M. Gribble, K. Schoonjans, F. Pattou, A. Tailleux, B. Staels, S. Lestavel, Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells. Nat. Commun. 6, 7629 (2015). https://doi.org/10.1038/ncomms8629CrossRefPubMed

85.

M.M. Holter, M.K. Chirikjian, V.N. Govani, and B.P. Cummings, TGR5 signaling in hepatic metabolic health. Nutrients 12(9), (2020). https://doi.org/10.3390/nu12092598

86.

M. Watanabe, S.M. Houten, C. Mataki, M.A. Christoffolete, B.W. Kim, H. Sato, N. Messaddeq, J.W. Harney, O. Ezaki, T. Kodama, K. Schoonjans, A.C. Bianco, J. Auwerx, Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439(7075), 484–489 (2006). https://doi.org/10.1038/nature04330CrossRefPubMed

87.

C. Thomas, A. Gioiello, L. Noriega, A. Strehle, J. Oury, G. Rizzo, A. Macchiarulo, H. Yamamoto, C. Mataki, M. Pruzanski, R. Pellicciari, J. Auwerx, K. Schoonjans, TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab. 10(3), 167–177 (2009). https://doi.org/10.1016/j.cmet.2009.08.001CrossRefPubMedPubMedCentral

88.

J.Y.L. Chiang, J.M. Ferrell, Bile acids as metabolic regulators and nutrient sensors. Annu. Rev. Nutr. 39, 175–200 (2019). https://doi.org/10.1146/annurev-nutr-082018-124344CrossRefPubMedPubMedCentral

89.

K.K. Ryan, R. Kohli, R. Gutierrez-Aguilar, S.G. Gaitonde, S.C. Woods, R.J. Seeley, Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154(1), 9–15 (2013). https://doi.org/10.1210/en.2012-1891CrossRefPubMed

90.

C.R. Martin, V. Osadchiy, A. Kalani, E.A. Mayer, The brain-gut-microbiome axis. Cell Mol. Gastroenterol. Hepatol. 6(2), 133–148 (2018). https://doi.org/10.1016/j.jcmgh.2018.04.003CrossRefPubMedPubMedCentral

91.

G. Marcelin, Y.H. Jo, X. Li, G.J. Schwartz, Y. Zhang, N.J. Dun, R.M. Lyu, C. Blouet, J.K. Chang, S. Chua Jr., Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol. Metab. 3(1), 19–28 (2014). https://doi.org/10.1016/j.molmet.2013.10.002CrossRefPubMed

92.

P. Pathak, C. Xie, R.G. Nichols, J.M. Ferrell, S. Boehme, K.W. Krausz, A.D. Patterson, F.J. Gonzalez, J.Y.L. Chiang, Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.Hepatology 68(4), 1574–1588 (2018). https://doi.org/10.1002/hep.29857CrossRefPubMed

93.

S. Moehn, P.B. Pencharz, R.O. Ball, Lessons learned regarding symptoms of tryptophan deficiency and excess from animal requirement studies. J. Nutr. 142(12), 2231s–2235s (2012). https://doi.org/10.3945/jn.112.159061CrossRefPubMed

94.

K. Gao, C.L. Mu, A. Farzi, W.Y. Zhu, Tryptophan metabolism: a link between the gut microbiota and brain. Adv. Nutr. 11(3), 709–723 (2020). https://doi.org/10.1093/advances/nmz127CrossRefPubMed

95.

D.Y. Kim, M. Camilleri, Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 95(10), 2698–2709 (2000). https://doi.org/10.1111/j.1572-0241.2000.03177.xCrossRefPubMed

96.

T. Mazda, H. Yamamoto, M. Fujimura, M. Fujimiya, Gastric distension-induced release of 5-HT stimulates c-fos expression in specific brain nuclei via 5-HT3 receptors in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. 287(1), G228–G235 (2004). https://doi.org/10.1152/ajpgi.00373.2003CrossRefPubMed

97.

L.A. Jones, E.W. Sun, A.M. Martin, D.J. Keating, The ever-changing roles of serotonin. Int. J. Biochem. Cell Biol. 125, 105776 (2020). https://doi.org/10.1016/j.biocel.2020.105776CrossRefPubMed

98.

N. Mou, Z. Duan, P. Ma, R. Fu, D. Fan, Study on the hypnotic effect of rare protopanaxadiol-type and protopanaxatriol-type ginsenosides. RSC Adv. 9(35), 20483–20491 (2019). https://doi.org/10.1039/c9ra01549cCrossRefPubMedPubMedCentral

99.

S.T. Breisch, F.P. Zemlan, B.G. Hoebel, Hyperphagia and obesity following serotonin depletion by intraventricular p-chlorophenylalanine. Science 192(4237), 382–385 (1976). https://doi.org/10.1126/science.130678CrossRefPubMed

100.

Y. Cai, X. Li, H. Zhou, J. Zhou, The serotonergic system dysfunction in diabetes mellitus. Front. Cell Neurosci. 16, 899069 (2022). https://doi.org/10.3389/fncel.2022.899069CrossRefPubMedPubMedCentral

101.

L. Zhou, G.M. Sutton, J.J. Rochford, R.K. Semple, D.D. Lam, L.J. Oksanen, Z.D. Thornton-Jones, P.G. Clifton, C.Y. Yueh, M.L. Evans, R.J. McCrimmon, J.K. Elmquist, A.A. Butler, L.K. Heisler, Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 6(5), 398–405 (2007). https://doi.org/10.1016/j.cmet.2007.10.008CrossRefPubMedPubMedCentral

102.

H. Ahlman, Nilsson, The gut as the largest endocrine organ in the body. Ann. Oncol. 12 Suppl 2, S63–S68 (2001). https://doi.org/10.1093/annonc/12.suppl_2.s63CrossRefPubMed

103.

R. Latorre, C. Sternini, R. De Giorgio, B. Greenwood-Van Meerveld, Enteroendocrine cells: a review of their role in brain-gut communication. Neurogastroenterol. Motil. 28(5), 620–630 (2016). https://doi.org/10.1111/nmo.12754CrossRefPubMed

104.

C. Sternini, L. Anselmi, E. Rozengurt, Enteroendocrine cells: a site of ‘taste’ in gastrointestinal chemosensing. Curr. Opin. Endocrinol. Diabetes Obes. 15(1), 73–78 (2008). https://doi.org/10.1097/MED.0b013e3282f43a73CrossRefPubMedPubMedCentral

105.

S.Z. Wang, Y.J. Yu, and K. Adeli, Role of gut microbiota in neuroendocrine regulation of carbohydrate and lipid metabolism via the microbiota-gut-brain-liver axis. Microorganisms 8(4), (2020). https://doi.org/10.3390/microorganisms8040527

106.

G.J. Dockray, Enteroendocrine cell signalling via the vagus nerve. Curr. Opin. Pharm. 13(6), 954–958 (2013). https://doi.org/10.1016/j.coph.2013.09.007CrossRef

107.

M.M. Kaelberer, K.L. Buchanan, M.E. Klein, B.B. Barth, M.M. Montoya, X. Shen, and D.V. Bohórquez, A gut-brain neural circuit for nutrient sensory transduction. Science 361(6408), (2018). https://doi.org/10.1126/science.aat5236

108.

K.G. Margolis, J.F. Cryan, E.A. Mayer, The microbiota-gut-brain axis: from motility to mood. Gastroenterology 160(5), 1486–1501 (2021). https://doi.org/10.1053/j.gastro.2020.10.066CrossRefPubMed

109.

S.F. Mehdi, S. Pusapati, M.S. Anwar, D. Lohana, P. Kumar, S.A. Nandula, F.K. Nawaz, K. Tracey, H. Yang, D. LeRoith, M.J. Brownstein, J. Roth, Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front. Immunol. 14, 1148209 (2023). https://doi.org/10.3389/fimmu.2023.1148209CrossRefPubMedPubMedCentral

110.

T.D. Müller, B. Finan, S.R. Bloom, D. D’Alessio, D.J. Drucker, P.R. Flatt, A. Fritsche, F. Gribble, H.J. Grill, J.F. Habener, J.J. Holst, W. Langhans, J.J. Meier, M.A. Nauck, D. Perez-Tilve, A. Pocai, F. Reimann, D.A. Sandoval, T.W. Schwartz, R.J. Seeley, K. Stemmer, M. Tang-Christensen, S.C. Woods, R.D. DiMarchi, M.H. Tschöp, Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72–130 (2019). https://doi.org/10.1016/j.molmet.2019.09.010CrossRefPubMedPubMedCentral

111.

S. Trapp, D.I. Brierley, Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment. Br. J. Pharm. 179(4), 557–570 (2022). https://doi.org/10.1111/bph.15638CrossRef

112.

C. Knauf, P.D. Cani, C. Perrin, M.A. Iglesias, J.F. Maury, E. Bernard, F. Benhamed, T. Grémeaux, D.J. Drucker, C.R. Kahn, J. Girard, J.F. Tanti, N.M. Delzenne, C. Postic, R. Burcelin, Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J. Clin. Invest. 115(12), 3554–3563 (2005). https://doi.org/10.1172/jci25764CrossRefPubMedPubMedCentral

113.

E.S. Bliss, E. Whiteside, The gut-brain axis, the human gut microbiota and their integration in the development of obesity. Front. Physiol. 9, 900 (2018). https://doi.org/10.3389/fphys.2018.00900CrossRefPubMedPubMedCentral

114.

L. Jia, S. Huang, B. Sun, Y. Shang, C. Zhu, Pharmacomicrobiomics and type 2 diabetes mellitus: a novel perspective towards possible treatment. Front. Endocrinol.14, 1149256 (2023). https://doi.org/10.3389/fendo.2023.1149256CrossRef

115.

L. Wang, P. Li, Z. Tang, X. Yan, B. Feng, Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment. Sci. Rep. 6, 33251 (2016). https://doi.org/10.1038/srep33251CrossRefPubMedPubMedCentral

116.

A.A. Greenwell, J.J. Chahade, J.R. Ussher, Cardiovascular biology of the GIP receptor. Peptides 125, 170228 (2020). https://doi.org/10.1016/j.peptides.2019.170228CrossRefPubMed

117.

C.W. Chia, J.M. Egan, Incretins in obesity and diabetes. Ann. N. Y Acad. Sci. 1461(1), 104–126 (2020). https://doi.org/10.1111/nyas.14211CrossRefPubMed

118.

J. Dupre, S.A. Ross, D. Watson, J.C. Brown, Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 37(5), 826–828 (1973). https://doi.org/10.1210/jcem-37-5-826CrossRefPubMed

119.

P. Richards, N.A. Thornberry, S. Pinto, The gut-brain axis: identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. Mol. Metab. 46, 101175 (2021). https://doi.org/10.1016/j.molmet.2021.101175CrossRefPubMedPubMedCentral

120.

A.E. Adriaenssens, E.K. Biggs, T. Darwish, J. Tadross, T. Sukthankar, M. Girish, J. Polex-Wolf, B.Y. Lam, I. Zvetkova, W. Pan, D. Chiarugi, G.S.H. Yeo, C. Blouet, F.M. Gribble, F. Reimann, Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. Cell Metab. 30(5), 987–996.e6 (2019). https://doi.org/10.1016/j.cmet.2019.07.013CrossRefPubMedPubMedCentral

121.

K. Miyawaki, Y. Yamada, N. Ban, Y. Ihara, K. Tsukiyama, H. Zhou, S. Fujimoto, A. Oku, K. Tsuda, S. Toyokuni, H. Hiai, W. Mizunoya, T. Fushiki, J.J. Holst, M. Makino, A. Tashita, Y. Kobara, Y. Tsubamoto, T. Jinnouchi, T. Jomori, Y. Seino, Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 8(7), 738–742 (2002). https://doi.org/10.1038/nm727CrossRefPubMed

122.

T. Min, S.C. Bain, The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials. Diabetes Ther. 12(1), 143–157 (2021). https://doi.org/10.1007/s13300-020-00981-0CrossRefPubMed

123.

M.K. Thomas, A. Nikooienejad, R. Bray, X. Cui, J. Wilson, K. Duffin, Z. Milicevic, A. Haupt, D.A. Robins, Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 106(2), 388–396 (2021). https://doi.org/10.1210/clinem/dgaa863CrossRefPubMed

124.

M. Dufresne, C. Seva, D. Fourmy, Cholecystokinin and gastrin receptors. Physiol. Rev. 86(3), 805–847 (2006). https://doi.org/10.1152/physrev.00014.2005CrossRefPubMed

125.

L.I. Larsson, J.F. Rehfeld, Localization and molecular heterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. 165(2), 201–218 (1979). https://doi.org/10.1016/0006-8993(79)90554-7CrossRefPubMed

126.

R. Chandra, R.A. Liddle, Cholecystokinin. Curr. Opin. Endocrinol. Diabetes Obes. 14(1), 63–67 (2007). https://doi.org/10.1097/MED.0b013e3280122850CrossRefPubMed

127.

G.W. Cheung, A. Kokorovic, C.K. Lam, M. Chari, T.K. Lam, Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab. 10(2), 99–109 (2009). https://doi.org/10.1016/j.cmet.2009.07.005CrossRefPubMed

128.

W. Fan, K.L. Ellacott, I.G. Halatchev, K. Takahashi, P. Yu, R.D. Cone, Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat. Neurosci. 7(4), 335–336 (2004). https://doi.org/10.1038/nn1214CrossRefPubMed

129.

B. Ahrén, J.J. Holst, S. Efendic, Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 85(3), 1043–1048 (2000). https://doi.org/10.1210/jcem.85.3.6431CrossRefPubMed

130.

K. Kasarello, A. Cudnoch-Jedrzejewska, K. Czarzasta, Communication of gut microbiota and brain via immune and neuroendocrine signaling. Front. Microbiol. 14, 1118529 (2023). https://doi.org/10.3389/fmicb.2023.1118529CrossRefPubMedPubMedCentral

131.

L.D. Godoy, M.T. Rossignoli, P. Delfino-Pereira, N. Garcia-Cairasco, E.H. de Lima Umeoka, A comprehensive overview on stress neurobiology: basic concepts and clinical implications. Front. Behav. Neurosci. 12, 127 (2018). https://doi.org/10.3389/fnbeh.2018.00127CrossRefPubMedPubMedCentral

132.

C.J. Hoogendoorn, J.F. Roy, J.S. Gonzalez, Shared dysregulation of homeostatic brain-body pathways in depression and type 2 diabetes. Curr. Diabetes Rep. 17(10), 90 (2017). https://doi.org/10.1007/s11892-017-0923-yCrossRef

133.

L.M. Frankiensztajn, E. Elliott, O. Koren, The microbiota and the hypothalamus-pituitary-adrenocortical (HPA) axis, implications for anxiety and stress disorders. Curr. Opin. Neurobiol. 62, 76–82 (2020). https://doi.org/10.1016/j.conb.2019.12.003CrossRefPubMed

134.

Y. Lin, Z. Zhang, S. Wang, J. Cai, J. Guo, Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders. Rev. Endocr. Metab. Disord. 21(4), 421–429 (2020). https://doi.org/10.1007/s11154-020-09586-1CrossRefPubMed

135.

I. Kokkinopoulou, A. Diakoumi, and P. Moutsatsou, Glucocorticoid receptor signaling in diabetes. Int. J. Mol. Sci. 22(20), (2021). https://doi.org/10.3390/ijms222011173

136.

U. Smith, Abdominal obesity: a marker of ectopic fat accumulation. J. Clin. Invest. 125(5), 1790–1792 (2015). https://doi.org/10.1172/jci81507CrossRefPubMedPubMedCentral

137.

B. Misiak, I. Łoniewski, W. Marlicz, D. Frydecka, A. Szulc, L. Rudzki, J. Samochowiec, The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota?. Prog. Neuropsychopharmacol. Biol. Psychiatry 102, 109951 (2020). https://doi.org/10.1016/j.pnpbp.2020.109951CrossRefPubMed

138.

K. Manohar, F.M. Mesfin, J. Liu, W.C. Shelley, J.P. Brokaw, T.A. Markel, Gut-Brain cross talk: the pathogenesis of neurodevelopmental impairment in necrotizing enterocolitis. Front. Pediatr. 11, 1104682 (2023). https://doi.org/10.3389/fped.2023.1104682CrossRefPubMedPubMedCentral

139.

J.R. Kelly, P.J. Kennedy, J.F. Cryan, T.G. Dinan, G. Clarke, N.P. Hyland, Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front. Cell Neurosci. 9, 392 (2015). https://doi.org/10.3389/fncel.2015.00392CrossRefPubMedPubMedCentral

140.

D.A. Winer, H. Luck, S. Tsai, S. Winer, The intestinal immune system in obesity and insulin resistance. Cell Metab. 23(3), 413–426 (2016). https://doi.org/10.1016/j.cmet.2016.01.003CrossRefPubMed

141.

K.Y. Hur, M.S. Lee, Gut microbiota and metabolic disorders. Diabetes Metab. J. 39(3), 198–203 (2015). https://doi.org/10.4093/dmj.2015.39.3.198CrossRefPubMedPubMedCentral

142.

P.D. Cani, J. Amar, M.A. Iglesias, M. Poggi, C. Knauf, D. Bastelica, A.M. Neyrinck, F. Fava, K.M. Tuohy, C. Chabo, A. Waget, E. Delmée, B. Cousin, T. Sulpice, B. Chamontin, J. Ferrières, J.F. Tanti, G.R. Gibson, L. Casteilla, N.M. Delzenne, M.C. Alessi, R. Burcelin, Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7), 1761–1772 (2007). https://doi.org/10.2337/db06-1491CrossRefPubMed

143.

K. de Punder, L. Pruimboom, Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Front. Immunol. 6, 223 (2015). https://doi.org/10.3389/fimmu.2015.00223CrossRefPubMedPubMedCentral

144.

S. Mohammad, C. Thiemermann, Role of metabolic endotoxemia in systemic inflammation and potential interventions. Front. Immunol. 11, 594150 (2020). https://doi.org/10.3389/fimmu.2020.594150CrossRefPubMed

145.

W. He, O. Rebello, R. Savino, R. Terracciano, C. Schuster-Klein, B. Guardiola, K. Maedler, TLR4 triggered complex inflammation in human pancreatic islets. Biochim. Biophys. Acta Mol. Basis Dis. 1865(1), 86–97 (2019). https://doi.org/10.1016/j.bbadis.2018.09.030CrossRefPubMed

146.

X. Li, Y. Cai, Z. Zhang, J. Zhou, Glial and vascular cell regulation of the blood-brain barrier in diabetes. Diabetes Metab. J. 46(2), 222–238 (2022). https://doi.org/10.4093/dmj.2021.0146CrossRefPubMedPubMedCentral

147.

M.T. Herrero, C. Estrada, L. Maatouk, S. Vyas, Inflammation in Parkinson’s disease: role of glucocorticoids. Front. Neuroanat. 9, 32 (2015). https://doi.org/10.3389/fnana.2015.00032CrossRefPubMedPubMedCentral

148.

D. Erny, A.L. Hrabě de Angelis, D. Jaitin, P. Wieghofer, O. Staszewski, E. David, H. Keren-Shaul, T. Mahlakoiv, K. Jakobshagen, T. Buch, V. Schwierzeck, O. Utermöhlen, E. Chun, W.S. Garrett, K.D. McCoy, A. Diefenbach, P. Staeheli, B. Stecher, I. Amit, M. Prinz, Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 18(7), 965–977 (2015). https://doi.org/10.1038/nn.4030CrossRefPubMedPubMedCentral

149.

A. Parker, S. Fonseca, S.R. Carding, Gut microbes and metabolites as modulators of blood-brain barrier integrity and brain health. Gut Microbes 11(2), 135–157 (2020). https://doi.org/10.1080/19490976.2019.1638722CrossRefPubMed

150.

V. Braniste, M. Al-Asmakh, C. Kowal, F. Anuar, A. Abbaspour, M. Tóth, A. Korecka, N. Bakocevic, L.G. Ng, P. Kundu, B. Gulyás, C. Halldin, K. Hultenby, H. Nilsson, H. Hebert, B.T. Volpe, B. Diamond, S. Pettersson, The gut microbiota influences blood-brain barrier permeability in mice. Sci. Transl. Med. 6(263), 263ra158 (2014). https://doi.org/10.1126/scitranslmed.3009759CrossRefPubMedPubMedCentral

151.

X. Peng, Z. Luo, S. He, L. Zhang, Y. Li, Blood-brain barrier disruption by lipopolysaccharide and sepsis-associated encephalopathy. Front Cell Infect. Microbiol. 11, 768108 (2021). https://doi.org/10.3389/fcimb.2021.768108CrossRefPubMedPubMedCentral

152.

M. Kalyan, A.H. Tousif, S. Sonali, C. Vichitra, T. Sunanda, S.S. Praveenraj, B. Ray, V.R. Gorantla, W. Rungratanawanich, A.M. Mahalakshmi, M.W. Qoronfleh, T.M. Monaghan, B.J. Song, M.M. Essa, and S.B. Chidambaram, Role of endogenous lipopolysaccharides in neurological disorders. Cells 11(24), (2022). https://doi.org/10.3390/cells11244038

153.

Z.H. Li, Y.Y. Jiang, C.Y. Long, Q. Peng, R.S. Yue, The gut microbiota-astrocyte axis: Implications for type 2 diabetic cognitive dysfunction. CNS Neurosci. Ther. 29 Suppl 1(Suppl 1), 59–73 (2023). https://doi.org/10.1111/cns.14077CrossRefPubMed

154.

A.M. Stranahan, S. Hao, A. Dey, X. Yu, B. Baban, Blood-brain barrier breakdown promotes macrophage infiltration and cognitive impairment in leptin receptor-deficient mice. J. Cereb. Blood Flow. Metab. 36(12), 2108–2121 (2016). https://doi.org/10.1177/0271678x16642233CrossRefPubMedPubMedCentral

155.

T.P.M. Scheithauer, E. Rampanelli, M. Nieuwdorp, B.A. Vallance, C.B. Verchere, D.H. van Raalte, H. Herrema, Gut microbiota as a trigger for metabolic inflammation in obesity and type 2 diabetes. Front. Immunol. 11, 571731 (2020). https://doi.org/10.3389/fimmu.2020.571731CrossRefPubMedPubMedCentral

156.

Y. Date, M. Kojima, H. Hosoda, A. Sawaguchi, M.S. Mondal, T. Suganuma, S. Matsukura, K. Kangawa, M. Nakazato, Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141(11), 4255–4261 (2000). https://doi.org/10.1210/endo.141.11.7757CrossRefPubMed

157.

G. Pradhan, S.L. Samson, Y. Sun, Ghrelin: much more than a hunger hormone. Curr. Opin. Clin. Nutr. Metab. Care 16(6), 619–624 (2013). https://doi.org/10.1097/MCO.0b013e328365b9beCrossRefPubMedPubMedCentral

158.

Q. Zeng, L. Ou, W. Wang, D.Y. Guo, Gastrin, cholecystokinin, signaling, and biological activities in cellular processes. Front. Endocrinol. 11, 112 (2020). https://doi.org/10.3389/fendo.2020.00112CrossRef

159.

M. Liguz-Lecznar, G. Dobrzanski, and M. Kossut, Somatostatin and somatostatin-containing interneurons-from plasticity to pathology. Biomolecules 12(2), (2022). https://doi.org/10.3390/biom12020312

160.

Y. Wu, H. He, Z. Cheng, Y. Bai, X. Ma, The role of neuropeptide Y and peptide YY in the development of obesity via gut-brain axis. Curr. Protein Pept. Sci. 20(7), 750–758 (2019). https://doi.org/10.2174/1389203720666190125105401CrossRefPubMed

161.

A. De Silva, S.R. Bloom, Gut hormones and appetite control: a focus on PYY and GLP-1 as therapeutic targets in obesity. Gut Liver 6(1), 10–20 (2012). https://doi.org/10.5009/gnl.2012.6.1.10CrossRefPubMedPubMedCentral

162.

K.C. Coate, S.A. Kliewer, D.J. Mangelsdorf, SnapShot: hormones of the gastrointestinal tract. Cell 159(6), 1478.e1 (2014). https://doi.org/10.1016/j.cell.2014.11.026CrossRefPubMed

Titel: Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis
verfasst von: Yi Pan
Tong Bu
Xia Deng
Jue Jia
Guoyue Yuan
Publikationsdatum: 16.01.2024
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2024
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-023-03640-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Gut microbiota and type 2 diabetes mellitus: a focus on the gut-brain axis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2024

Mechanisms and risk factors of metabolic syndrome in children and adolescents

Value of repeated US-guided fine-needle aspiration (US-FNAB) in the follow-up of benign thyroid nodules: a real-life study based on the MoCyThy (Modena’s Cytology of the Thyroid) DATABASE with a revision of the literature

A critical evaluation of pictogram based patient information leaflet on hypothyroidism patients with metabolic syndrome: a visual approach to enhance health literacy

Effects of eight-week regular high-intensity interval training and hemp (Cannabis sativa L.) seed on total testosterone level among sedentary young males: double-blind, randomized, controlled clinical trial

Polymorphisms in the Runx2 and osteocalcin genes affect BMD in postmenopausal women: a systematic review and meta-analysis

The identification of a novel mutation (p.I223fs) in WRN associated with Werner syndrome

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin